The adolescent trial (AD-1526) was a 16-week monotherapy study with patients 12-17 years of age with moderate-to-severe atopic dermatitis.1
The trial in children (AD-1652) was a 16-week concomitant TCS use study with patients 6-11 years of age with severe atopic dermatitis.1
See DUPIXENT Study